CRL-2557 Panc 05.04細(xì)胞， 人胰腺癌細(xì)胞
| 參考價(jià) | ￥ 1 |
| 訂貨量 | ≥1 件 |
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海復(fù)祥生物科技有限公司
- 品牌 其他品牌
- 型號(hào) CRL-2557
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/8/14 12:05:44
- 訪問(wèn)次數(shù) 1746
產(chǎn)品標(biāo)簽
聯(lián)系方式：李經(jīng)理15000266580 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
ATCC 細(xì)胞,細(xì)胞系,細(xì)胞株,腫瘤細(xì)胞,細(xì)胞,ATCC 菌種，CMCC 菌種，標(biāo)準(zhǔn)菌株，質(zhì)控菌種，微生物菌種，菌株，菌種
| 供貨周期 | 一周 | 規(guī)格 | T25 |
|---|---|---|---|
| 貨號(hào) | Panc | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥/生物制藥 |
| 主要用途 | 科學(xué)研究 |
Panc 05.04細(xì)胞， 人胰腺癌細(xì)胞
| ATCC® Number: | CRL-2557™ | Price: | $417.00 |
| Designations:Panc 05.04Depositors:EM JaffeeBiosafety Level:1Shipped:frozenMedium & Serum:See PropagationGrowth Properties:adherentOrganism:Homo sapiens (human)Morpholoepithelial Source:gy:Organ: pancreas Disease: adenocarcinomaCellular Products:cytokeratins 7 and 18 [50655]Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.Panc 05.04細(xì)胞， 人胰腺癌細(xì)胞Isolation:Isolation date: May 5, 1995Tumorigenic:YesOncogene:K-ras +Antigen Expression:MHC class I +; MHC class II - [50655] Blood type B; Rh+Age:77 years adultGender:femaleEthnicity:WhiteComments:Panc 05.04 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] The cells have a reported plating efficiency of 100%. [50655]Propagation:ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 20 Units/ml human recombinant insulin, 85%; fetal bovine serum, 15%Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°CSubculturing:Protocol: Remove and discard culture medium.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.To remove trypsin-EDTA solution, transfer cell suspension to centrifuge tube and spin at approximay 125 xg for 5 to 10 minutes.Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels.Incubate cultures at 37°C.Subc*tion Ratio: A subc*tion ratio of 1:3 to 1:5 is recommended Medium Renewal: Add media once per week. Fluid change one to two times per week.Preservation:Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phaseDoubling Time:46 hrsRelated Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001recommended serum:ATCC 30-2020References:50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 | |||
采購(gòu)中心
化工儀器網(wǎng)